The ACE2 Knockout KYSE-30 Polyclonal Cells product provides a heterogeneous pool of CRISPR/Cas9-edited KYSE-30 human esophageal squamous cell carcinoma cells carrying targeted disruptions in the ACE2 gene. As a polyclonal knockout population, it bypasses single-cell cloning, thereby retaining the native genetic variability of the parental cell line. This configuration supports reliable gene-function analyses under conditions that better represent the original tumor cell diversity. Its utility extends to population-based assays where averaged responses are informative, and it offers a cost-effective alternative to clonal knockout lines.
The KYSE-30 cell line originated from a poorly differentiated esophageal squamous cell carcinoma and is a standard in vitro model for esophageal cancer research. These adherent epithelial cells faithfully recapitulate key malignant features, including uncontrolled proliferation and migratory capacity. They endogenously express multiple RAS components, providing a physiologically relevant background to study ACE2 within oncogenic signaling networks. KYSE-30??s widespread use in drug sensitivity and invasion assays further enhances the translational potential of this knockout model.
ACE2 is a carboxypeptidase that converts angiotensin II into angiotensin-(1-7), which activates the Mas receptor to counteract classical RAS-driven signaling. Upstream, ACE2 activity is regulated by ADAM17-mediated shedding, renin-driven substrate levels, and interferon-induced transcription. It also serves as the cell-surface receptor for SARS-CoV and SARS-CoV-2 spike proteins, with B0AT1 and collectrin acting as cofactors. Downstream angiotensin-(1-7)/Mas signaling influences pathways such as nitric oxide production and MAPK cascades, impacting cell growth and survival.
In esophageal squamous cell carcinoma, altered ACE2 expression may shape tumor progression via local angiotensin peptide balance. The ACE2 Knockout KYSE-30 Polyclonal Cells permit dissection of cell-autonomous and paracrine roles of ACE2 in this context. Researchers can examine how ACE2 loss affects cancer cell proliferation, migration, and apoptosis, and assess crosstalk with the viral entry machinery. Additionally, it allows interrogation of ACE2-dependent responses to angiotensin peptides and viral challenge.
Typical applications include ACE2 enzymatic activity measurement, RT-qPCR and Western blot analyses of pathway markers, and ELISA detection of angiotensin peptides. Viral pseudotype entry assays using SARS-CoV-2 spike-expressing vectors can be employed to study ACE2-mediated infection in esophageal cancer cells. Functional assays such as proliferation, migration, and apoptosis readouts further elucidate the gene??s role in tumor biology. The pool also supports drug screens for ACE2 modulators. For further information, contact Ascent Research.
